Taiwan
· Delayed Price · Currency is TWD Lumosa Therapeutics Statistics
Total Valuation
Lumosa Therapeutics has a market cap or net worth of TWD 61.44 billion. The enterprise value is 60.91 billion.
| Market Cap | 61.44B |
| Enterprise Value | 60.91B |
Important Dates
The last earnings date was Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lumosa Therapeutics has 164.93 million shares outstanding. The number of shares has decreased by -0.50% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 164.93M |
| Shares Change (YoY) | -0.50% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 1.62% |
| Owned by Institutions (%) | 5.60% |
| Float | 89.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 52.55 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -156.67 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -222.74 |
Financial Position
The company has a current ratio of 3.74, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.74 |
| Quick Ratio | 2.96 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -2,376.73 |
Financial Efficiency
Return on equity (ROE) is -29.64% and return on invested capital (ROIC) is -16.00%.
| Return on Equity (ROE) | -29.64% |
| Return on Assets (ROA) | -14.04% |
| Return on Capital (ROIC) | -16.00% |
| Revenue Per Employee | 804,574 |
| Profits Per Employee | -8.27M |
| Employee Count | 47 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.14 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +497.96% in the last 52 weeks. The beta is 0.37, so Lumosa Therapeutics's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +497.96% |
| 50-Day Moving Average | 317.66 |
| 200-Day Moving Average | 225.64 |
| Relative Strength Index (RSI) | 64.31 |
| Average Volume (20 Days) | 932,930 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lumosa Therapeutics had revenue of TWD 37.82 million and -388.80 million in losses. Loss per share was -2.40.
| Revenue | 37.82M |
| Gross Profit | 23.85M |
| Operating Income | -349.38M |
| Pretax Income | -402.82M |
| Net Income | -388.80M |
| EBITDA | -341.39M |
| EBIT | -349.38M |
| Loss Per Share | -2.40 |
Balance Sheet
The company has 555.62 million in cash and 9.51 million in debt, giving a net cash position of 546.11 million or 3.31 per share.
| Cash & Cash Equivalents | 555.62M |
| Total Debt | 9.51M |
| Net Cash | 546.11M |
| Net Cash Per Share | 3.31 |
| Equity (Book Value) | 1.18B |
| Book Value Per Share | 7.09 |
| Working Capital | 537.63M |
Cash Flow
In the last 12 months, operating cash flow was -270.50 million and capital expenditures -2.97 million, giving a free cash flow of -273.46 million.
| Operating Cash Flow | -270.50M |
| Capital Expenditures | -2.97M |
| Free Cash Flow | -273.46M |
| FCF Per Share | -1.66 |
Margins
| Gross Margin | 63.08% |
| Operating Margin | -923.92% |
| Pretax Margin | -1,065.24% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -723.16% |
Dividends & Yields
Lumosa Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.50% |
| Shareholder Yield | 0.50% |
| Earnings Yield | -0.65% |
| FCF Yield | -0.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |